Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effect of two medicines on COPD (Chronic Obstructive Pulmonary
Disease) exacerbations. This study will last up to 56 weeks, and subjects will visit the
clinic 10 times. Subjects will be given breathing tests and will record their breathing
symptoms daily on diary cards. All study related medicines and medical examinations will be
provided at no cost. The two drugs used in this study have been approved by FDA for use in
patients with COPD.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance